Enrique Ocio
Hospital Universitario Marqués de Valdecilla
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Enrique Ocio as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07901868 · Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple MyelomaPETHEMA Foundation · not yet recruiting · Multiple Myeloma Refractory, Multiple Myeloma in Relapse · principal investigator
- Ph1/Ph2NCT05908409 · A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic MalignanciesIDP Discovery Pharma S.L. · recruiting · Multiple Myeloma (MM), Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double Hit Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:14 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- 659 citationsRCR 17.6
- Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.Lancet Haematol · 2019219 citationsRCR 7.2
- 143 citationsRCR 4.8
- Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.Blood · 2016129 citationsRCR 4.1
- Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 2025104 citationsRCR 21.8
- 88 citationsRCR 2.8
- Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.Br J Haematol · 201969 citationsRCR 2.3
- Sequential vs alternating administration of VMP and Rd in elderly patients with newly diagnosed MM.Blood · 201657 citationsRCR 1.8
- 56 citationsRCR 3.2
- 49 citationsRCR 1.9